Differential Study of Muscle Transcriptome

Differential Study of Muscle Transcriptome in Patients With Neuromuscular Disease and Control Subjects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01984957

Acronym

TRANE

Enrollment

Registered

2013-11-15

Start date

2013-01-31

Completion date

2015-01-31

Last updated

2015-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALS, SBMA, SMA

Keywords

ALS, Motor neuron diseases, Transcriptome

Brief summary

To isolate biomarkers of ALS in muscle

Detailed description

At present, there is no validated biological diagnostic marker for amyotrophic lateral sclerosis (ALS). The main objective of the study is to isolate a set of genes that are specifically dysregulated in muscle from ALS patients. Gene profiling in muscle will be compared between ALS patients and patients with other motor neuron diseases (SMA and SBMA)

Interventions

PROCEDUREMuscle biopsy

open muscular biopsy of the deltoid under local anaesthesia

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

: \- Patient with ALS, SMA, or SBMA

Exclusion criteria

: * Indication against biopsy (allergy to anesthetics local haemostasis disorders) * Treatments that can affect muscle metabolism

Design outcomes

Primary

Measure	Time frame	Description
Gene expression levels	day 1	Gene expression levels in muscle as determined By microarrays (transcriptome analysis)

Secondary

Measure	Time frame	Description
muscle denervation	day 1	Severity of muscle denervation as determined by histological analysis of muscle
Functional evaluation	day 1	ALSFRS-R, Manual Muscle Testing and Slow Vital Capacity

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026